首页> 外文会议>Annual NSTI nanotechnology conference and expo >Epidermal growth factor-ferritin H-chain nanoparticles as nanocarrier of doxorubicin for overcoming drug resistance in human breast cancer cells
【24h】

Epidermal growth factor-ferritin H-chain nanoparticles as nanocarrier of doxorubicin for overcoming drug resistance in human breast cancer cells

机译:表皮生长因子-铁蛋白H链纳米颗粒作为阿霉素的纳米载体,用于克服人乳腺癌细胞的耐药性

获取原文

摘要

The emergence of drug-resistant cancer cells together with the side effects of chemotherapy agents are the major obstacle in cancer treatment. We focused on providing a new pattern of protein-based nanoparticle as drug delivery system. FTH1 is a kind of protein that exist in human body which has high bio-safety while EGFR is overexpressed in many cancer cells and it has been used as therapeutic target for cancer treatment. Thus, we used genetic methods for integrating EGF onto the surface of FTH1 and found out a more simple way to express the fusion proteins. To enhance the loading capacity, we first inserted a linker containing more sulfydryl sites (cysteine) into EGF-FTH1 and then adopted chemistry way to covalent bonding the doxorubicin to the nanoparticles. It was found that 72 of DOX molecular could be loaded to one nanoparticle, in vitro they could be released from the nanoparticles at pH5.0. These results demonstrate that the DOX/EGF-XCys-FTHl could be a very promising drug delivery system.
机译:耐药性癌细胞的出现以及化疗药物的副作用是癌症治疗的主要障碍。我们致力于提供一种新型的基于蛋白质的纳米颗粒作为药物递送系统。 FTH1是人体中存在的一种蛋白质,具有很高的生物安全性,而EGFR在许多癌细胞中均过表达,已被用作癌症的治疗靶标。因此,我们使用遗传方法将EGF整合到FTH1的表面,并发现了表达融合蛋白的更简单方法。为了提高负载能力,我们首先将包含更多巯基位点(半胱氨酸)的接头插入EGF-FTH1,然后采用化学方法将阿霉素与纳米颗粒共价键合。已发现72个DOX分子可以负载到一个纳米颗粒上,在体外它们可以在pH5.0下从纳米颗粒中释放出来。这些结果证明DOX / EGF-XCys-FTH1可能是非常有前途的药物递送系统。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号